Myocardial Infarction – Idorsia Pharmaceuticals ID-076A301
Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.
This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen et al. 2018) and having additional cardiovascular risk factors.
Main Inclusion Criteria:
- Confirmed diagnosis of symptomatic type 1 acute myocardial infarction (AMI) ST-Elevation Myocardial Infarction (STEMI) or Non-ST-Elevation Myocardial Infarction (NSTEMI), no longer than 4 weeks prior to randomization.
- Diagnosis of multivessel coronary artery disease defined as ≥ 50% stenosis on 2 or more coronary artery territories, including the left main artery, during a prior cardiac catheterization or cardiac catheterization during the qualifying AMI event and presence of at least 1 of the following risk factors:
- Second prior AMI,
- Diabetes mellitus defined by ongoing glucose lowering treatment,
- Chronic kidney disease defined as estimated glomerular filtration rate less than 60 mL/min/1.73 m2 and either known history of chronic kidney disease or a biomarker of chronic kidney damage,
- Peripheral artery disease at any time prior to randomization,
- Absence of, or unsuccessful coronary revascularization of the qualifying AMI.
- Successful self-administered placebo according to the autoinjector instruction for use training during screening.
- Other criteria may apply
Complete the form and our team will reach out soon to help determine your eligibility.
